BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 27726850)

  • 1. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
    De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
    Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
    Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.
    Hassanzadeh E; Alessandrino F; Olubiyi OI; Glazer DI; Mulkern RV; Fedorov A; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2018 May; 43(5):1237-1244. PubMed ID: 28840280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
    Jambor I; Kähkönen E; Taimen P; Merisaari H; Saunavaara J; Alanen K; Obsitnik B; Minn H; Lehotska V; Aronen HJ
    J Magn Reson Imaging; 2015 May; 41(5):1394-404. PubMed ID: 24956412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra- and interreader reproducibility of PI-RADSv2: A multireader study.
    Smith CP; Harmon SA; Barrett T; Bittencourt LK; Law YM; Shebel H; An JY; Czarniecki M; Mehralivand S; Coskun M; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2019 Jun; 49(6):1694-1703. PubMed ID: 30575184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen.
    Kuhl CK; Bruhn R; Krämer N; Nebelung S; Heidenreich A; Schrading S
    Radiology; 2017 Nov; 285(2):493-505. PubMed ID: 28727544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Local Recurrence of Prostate Cancer After Radical Prostatectomy Using Endorectal Coil MRI at 3 T: Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI.
    Kitajima K; Hartman RP; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    AJR Am J Roentgenol; 2015 Oct; 205(4):807-16. PubMed ID: 26397329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
    Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
    Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience.
    Di Campli E; Delli Pizzi A; Seccia B; Cianci R; d'Annibale M; Colasante A; Cinalli S; Castellan P; Navarra R; Iantorno R; Gabrielli D; Buffone A; Caulo M; Basilico R
    Eur J Radiol; 2018 Apr; 101():17-23. PubMed ID: 29571792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
    Park JJ; Park BK
    J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
    Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
    Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
    Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
    AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
    Gaur S; Harmon S; Gupta RT; Margolis DJ; Lay N; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    Acad Radiol; 2019 Jan; 26(1):5-14. PubMed ID: 29705281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate.
    Baur AD; Maxeiner A; Franiel T; Kilic E; Huppertz A; Schwenke C; Hamm B; Durmus T
    Invest Radiol; 2014 Jun; 49(6):411-20. PubMed ID: 24598440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
    Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility artifacts and PIRADS 3 lesions in prostatic MRI: how often is the dynamic contrast-enhance sequence necessary?
    Antunes N; Vas D; Sebastia C; Salvador R; Ribal MJ; Nicolau C
    Abdom Radiol (NY); 2021 Jul; 46(7):3401-3409. PubMed ID: 33683430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.